Fresenius Kabi launches IV Cancer Drug in the U.S.

Bortezomib for Injection, an affordable treatment option for adult patients with multiple myeloma and mantle cell lymphoma, is now available from Fresenius Kabi in the United States and indicated for two routes of administration – intravenous and subcutaneous. This is the newest addition to the company’s expansive oncology portfolio in the United States.